A STUDY CONDUCTED IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM); TO DETERMINE DOSE OF AFURESERTIB IN COMBINATION WITH CARFILZOMIB (PART 1) AND TO INVESTIGATE THE SAFETY, PHARMACOKINETIC AND CLINICAL ACTIVITY OF THE COMBINATION COMPARED WITH CARFILZOMIB ALONE (PART 2):